Pradofloxacin

Drugbox
IUPAC_name = 7- [(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo [3,4-b] pyridin-6-yl] -8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid

---

CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 9802884
DrugBank =
chemical_formula =
C=21 | H=21 | F=1 | N=4 | O=3
molecular_weight = 396.414 g/mol
smiles = C4C3NCCCC3CN4c1c(C#N)c2n(C5CC5)cc(C(=O)O)c(=O)c2cc1F
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Pradofloxacin (tradename Veraflox) is a quinolone antibiotic developed by Bayer AG, intended to treat infections in dogs and cats. The European Medicines Agency refused to grant marketing authorization for Veraflox, citing product safety and quality issues. [European Medicines Agency (2007). PDFlink| [http://www.emea.europa.eu/vetdocs/PDFs/EPAR/veraflox/EMEA-CVMP-342257-2007.pdf REFUSAL CHMP ASSESSMENT REPORT FOR VERAFLOX. Procedure No. EMEA/V/C/099] |279 KB. London: European Medicines Agency. Retrieved on 2008-06-23. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.]

References